PAT project

PAT project

Telormedix SA, a clinical stage biopharmaceutical company focusing on toll-like receptor 7 (TLR7) small molecules in the treatment of cancer and inflammatory diseases, raised funding from the European Eurostars Programme to coordinate an international research project involving a consortium of companies aimed at developing new formulations of one of the Company’s promising drug candidates, TMX-306, for the treatment of psoriasis. The psoriasis anti-inflammatory treatment project, operating under the acronym PAT, has a total budget of €1.77 M and involves consortium partners Biopta, Midatech Biogune, Molecular Profiles and the University Hospital Zurich (USZ).

The PAT project will initially focus on developing new oral and topical formulations of TMX-306 using Midatech’s nanoparticles formulated using Molecular Profile’s technology. Both routes of administration are viewed as practicable for the treatment of psoriasis. Once a range of formulations has been developed, Biopta will screen them by using human fresh tissue in vitro assays to select the best candidates. These candidates will then be studied and compared to currently used therapies in well-established humanized animal models of psoriasis at the Department of Dermatology of the USZ.

The Eurostars Programme is the European funding and support programme specifically dedicated to stimulating international collaborative research and innovation projects of small and medium enterprises. For further information on the Eurostars Programme, please visit: https://www.eurostars-eureka.eu/

Live chat by BoldChat